Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.

CNS oncology - 1 Oct 2016

Donovan Laura E, Arnal Ashley V, Wang Shih-Hsiu, Odia Yazmin

Abstract excerpt

Pituitary adenomas are the commonest intracranial tumor, but metastases are rare (0.2% yearly incidence) and portend poor prognosis. CAPecitabine and TEMozolomide improved outcomes for neuroendocrine tumors. However, no chemotherapy is approved for refractory pituitary carcinomas. Next-generation sequencing revealed an actionable mTOR pathway STK11 mutation in a woman with adrenocorticotropic hormone-secreting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenocorticotropic Hormone
Share to AMP-Activated Protein Kinase Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Dacarbazine

Share to Everolimus

Share to Ki-67 Antigen

Share to Pituitary Neoplasms

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 27615706
DOI: 10.2217/cns-2016-0011
PMCID: PMC6040044

Genes

STK11

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.PMID 27615706Read ↗

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.Semantic proximity Read ↗

The genome-wide mutational landscape of pituitary adenomasSemantic proximity Read ↗

Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.Semantic proximity Read ↗

Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.Semantic proximity Read ↗

MALAT1 rs619586 as a potential genetic marker of pituitary adenoma susceptibility and aggressiveness.Semantic proximity Read ↗

Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomasSemantic proximity Read ↗

Clinical characteristics associated with somatic GNAS mutations in acromegaly: a systematic review and institutional experience.Semantic proximity Read ↗

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma.Semantic proximity Read ↗

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.Semantic proximity Read ↗

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus.Semantic proximity Read ↗

Pituitary Adenoma: SSTR2 rs2236750, SSTR5 rs34037914, and AIP rs267606574 Genetic Variants, Serum Levels, and Ki-67 Labeling Index Associations.Semantic proximity Read ↗

Pituitary Metastasis as an Endocrine–Neuro-Ophthalmologic Emergency: Clinical Red Flags and Outcomes From a Contemporary Tertiary-Center SeriesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.